10-Q: Ludwig Enterprises Faces Going Concern Doubt

Ludwig Enterprises, a healthcare technology developer, reported significant financial deficits and a going concern warning, despite a reduced net loss.

Summary

• Ludwig Enterprises, Inc. is a Nevada Corporation focused on developing products and services using cutting-edge technologies in the healthcare industry, specifically mRNA-based genetic markers for inflammation and inflammatory-driven diseases.
• The company reported a net loss of $1,190,387 for the six months ended June 30, 2025, a decrease from $1,975,071 for the same period in 2024.
• Net cash used in operating activities increased to $500,797 for the six months ended June 30, 2025, compared to $331,428 in the prior year period.
• As of June 30, 2025, the company had a working capital deficit of $3,402,780, an accumulated deficit of $8,449,753, and a stockholders deficit of $3,402,160.
• The company had virtually no revenue, reporting $0 for the six months ended June 30, 2025, down from $10 in the prior year period.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within the next twelve months, citing insufficient revenues and positive cash flows.
• The company's disclosure controls and procedures over financial reporting were deemed not effective as of June 30, 2025, indicating material weaknesses.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warning, persistent lack of revenue, increasing financial deficits, and ineffective internal controls. While net loss decreased, the underlying financial health and operational cash burn remain critical concerns, heavily reliant on uncertain future capital raises.

Positives

• Net loss for the six months ended June 30, 2025, decreased to $1,190,387 from $1,975,071 in the prior year period.
• Cash on hand increased significantly to $142,474 at June 30, 2025, from $6,741 at December 31, 2024, primarily due to financing activities.
• The company successfully raised $750,000 in proceeds from convertible notes payable during the six months ended June 30, 2025.

Negatives

• The company reported virtually no revenue ($0) for the six months ended June 30, 2025, indicating a complete lack of commercialized products or services.
• Net cash used in operating activities increased to $500,797 for the six months ended June 30, 2025, reflecting a higher cash burn.
• Significant financial deficits persist, including a working capital deficit of $3,402,780, an accumulated deficit of $8,449,753, and a stockholders deficit of $3,402,160 as of June 30, 2025.
• Total liabilities increased substantially to $3,803,434 at June 30, 2025, from $2,575,701 at December 31, 2024, driven by a new derivative liability of $898,059.
• General and administrative expenses increased by $364,878 to $960,253 for the six months ended June 30, 2025, due to increased sales and marketing activities and professional fees.
• The company incurred a loss on extinguishment of debt of $117,217 during the six months ended June 30, 2025, due to modification of convertible note terms.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within the next twelve months.

Risks

• Inadequate capital and barriers to raising additional capital or obtaining the financing needed to implement business plans.
• Failure to earn revenues or profits, as the company currently generates virtually no revenue.
• Inadequate capital to continue business operations, leading to substantial doubt about the company's ability to continue as a going concern.
• Volatility or decline of the company's stock price.
• Potential fluctuation in quarterly results.
• Rapid and significant changes in markets, particularly in the healthcare technology sector.
• Insufficient revenues to cover operating costs, leading to ongoing losses and cash burn.

Future Outlook

The company expects revenues from sales of its planned products to begin during the fourth quarter of 2025, contingent on obtaining approximately $10,000,000 in needed funding, for which there is no assurance. Operating expenses for the full year 2025 are projected to exceed those incurred in 2024, assuming the company is able to secure the necessary capital to expand business activities.

Management Comments

• "We are an innovative technology and health related company that is developing products that use mRNA-based genetic markers with the potential to measure the presence of inflammation, and, as a result, inflammatory driven diseases and monitor patient response to treatment."
• "Advancements in medical technology have awarded us with cutting edge genetic tools, unheard of even a generation ago. These genetic tools have the potential to not only achieve early detection of diseases but also to support customized treatments that may improve patient outcomes."
• "Our company is at the forefront of this new era of medicine with development of products that will embody our proprietary mRNA genomic technology that has the potential of screening for genetic biomarkers for inflammatory driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID."
• "The Company does not expect to generate sufficient revenues and positive cash flows from operations to meet its current obligations. However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain."
• "These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued."
• "Managements strategic plans include: Execute business operations more fully during the year ended December 31, 2025; Seek out strategic acquisitions of health care technology; and Explore prospective partnership opportunities."

Industry Context

Ludwig Enterprises operates in the highly innovative but capital-intensive healthcare technology and biotechnology sector, specifically focusing on mRNA-based diagnostics for inflammatory diseases. This area is characterized by significant research and development costs, long development cycles, and high regulatory hurdles. The company's current state of virtually no revenue and reliance on external funding is common for early-stage biotech firms, but the explicit 'going concern' warning highlights a critical challenge in securing the necessary capital to advance its products to market amidst competitive pressures and the need for substantial investment in clinical validation and commercialization.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit of over $8.4 million is far below the commercialization stage of established healthcare technology companies.
• The reliance on external capital for continued operations and the explicit 'going concern' warning indicate a financial position significantly weaker than industry peers that have achieved product market fit or sustainable revenue streams.
• While increased R&D spending is typical for biotech, the absence of corresponding revenue generation or clear milestones for commercialization puts Ludwig Enterprises behind companies like Moderna or BioNTech at similar stages of mRNA technology development, which secured substantial funding and partnerships much earlier in their product lifecycles.
• The ineffective disclosure controls and procedures are a significant governance issue, contrasting sharply with the robust internal controls expected of publicly traded companies in the highly regulated healthcare sector.

Management Changes

Corporate Governance

Legal Proceedings

• No pending legal or administrative proceedings.

Related Party Transactions

• Outstanding balance due to related party increased to $45,101 at June 30, 2025, from $5,000 at December 31, 2024.
• A promissory note with a principal amount of $5,000 from the former CEO was redeemed in May 2025.
• A promissory note in the principal amount of $36,912 was issued to the current CEO (Scott J. Silverman) on March 10, 2025, maturing September 30, 2025, with an 8% interest rate.
• The CEO paid $15,247 in operating expenses on behalf of the company, of which $7,058 was repaid.
• Payments of $37,500 were made to Thornhill Advisory Group, Inc., a company beneficially owned by the CFO (Scott J. Silverman), for financial advisory services during the six months ended June 30, 2025, with $71,375 accrued in fees payable.
• Payments of $0 were made to Jose Antonio Reyes (former CEO) during the six months ended June 30, 2025, with $108,750 accrued in fees payable.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and automatic conversion of convertible notes upon uplisting. The 'going concern' warning indicates a high risk of capital loss.
• **Employees:** The company's precarious financial position and reliance on future funding may create job insecurity, particularly for key personnel whose compensation includes accrued fees.
• **Creditors:** Hold unsecured promissory notes and convertible notes, facing repayment risk given the company's liquidity challenges and going concern warning.
• **Customers:** (Potential future customers) The delay in product commercialization due to funding issues means no immediate benefit from the company's planned healthcare technology products.
• **Suppliers:** May face payment delays or non-payment given the company's working capital deficit and reliance on future capital raises.

Next Steps

• Execute business operations more fully during the year ended December 31, 2025.
• Seek out strategic acquisitions of healthcare technology.
• Explore prospective partnership opportunities.
• Obtain approximately $10,000,000 in funding to enable product revenue generation by Q4 2025.
• Continue evaluating the impact of the Taxpayer Fairness and Growth Act of 2025 and recognize any required adjustments in the period of enactment.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by an explicit 'going concern' warning, persistent lack of revenue, increasing deficits, and significant cash burn from operations. While the net loss decreased, this is largely due to non-recurring finance expenses in the prior period, not improved operational performance. The ineffective internal controls further compound governance risks. The company's future is entirely dependent on securing substantial, uncertain capital, which, if successful, will likely lead to significant shareholder dilution. Given the high risk of failure and lack of clear path to profitability, a strong sell recommendation is warranted.

Keywords

Healthcare Technology, mRNA, Genetic Markers, Inflammation, Biotechnology, Diagnostics, SEC Filing, 10-Q, Going Concern, Startup, Biopharma